Search research articles
Contact Us
Filters
Showing results (561-570 of 573) with videos related to
Page
of 58
Sort By:
Health Technology Assessment (Winchester, England)
|
December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
Romain Cohen, Dewi Vernerey, Carine Bellera, et al.
The Lancet. Oncology
|
April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Timothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
British Journal of Cancer
|
November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
José Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 29, 2024
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors
Kathryn A F Pennel, Phimmada Hatthakarnkul, Colin S Wood, et al.
The Lancet. Oncology
|
May 26, 2022
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
Lennard Y W Lee, Thomas Starkey, Maria C Ionescu, et al.
Nature Medicine
|
March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
Joris van de Haar, Xuhui Ma, Salo N Ooft, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 9, 2022
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study
Lennard Y W Lee, Maria C Ionescu, Thomas Starkey, et al.
JAMA Oncology
|
December 22, 2022
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation
Lennard Y W Lee, Michael Tilby, Thomas Starkey, et al.
Scientific Reports
|
July 25, 2023
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)
Thomas Starkey, Maria C Ionescu, Michael Tilby, et al.
Page
of 58
Search research articles
Search
Showing results (561-570 of 573) with videos related to
Sort By:
Page
of 58
Health Technology Assessment (Winchester, England)
|
December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
Romain Cohen, Dewi Vernerey, Carine Bellera, et al.
The Lancet. Oncology
|
April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
Timothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
British Journal of Cancer
|
November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
José Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 29, 2024
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors
Kathryn A F Pennel, Phimmada Hatthakarnkul, Colin S Wood, et al.
The Lancet. Oncology
|
May 26, 2022
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
Lennard Y W Lee, Thomas Starkey, Maria C Ionescu, et al.
Nature Medicine
|
March 2, 2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
Joris van de Haar, Xuhui Ma, Salo N Ooft, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 9, 2022
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study
Lennard Y W Lee, Maria C Ionescu, Thomas Starkey, et al.
JAMA Oncology
|
December 22, 2022
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation
Lennard Y W Lee, Michael Tilby, Thomas Starkey, et al.
Scientific Reports
|
July 25, 2023
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)
Thomas Starkey, Maria C Ionescu, Michael Tilby, et al.
Page
of 58